Skip to main content

Merck & Co., Inc.

MRK
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0000310158

In the last 90 days, Merck & Co., Inc. insiders filed 0 open-market purchases and 7 sales; 3,854 institutions reported holding it in 13F filings for Q2 2026, worth $254.7B in total; 4 superinvestors hold it, including Harris Associates (Oakmark) and Fairfax Financial.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $30.0M in total
7
13F holdersQ2 2026, +96 vs. previous quarter
3,854
13F valueReported value at the end of Q2 2026
$254.7B
Superinvestors holdingAt the end of Q2 2026
4

Price chart

Superinvestors holding MRK, Q2 2026

4 superinvestors report holding Merck & Co., Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

Harris Associates (Oakmark)

Bill Nygren

2.1%

Merck & Co., Inc.'s share of the portfolio

Shares
12,073,109
Value
$1.55B

Fairfax Financial

Prem Watsa

0.8%

Merck & Co., Inc.'s share of the portfolio

Shares
172,900
Value
$22.2M
Other superinvestors holding MRK (part 1)
SuperinvestorWeightValue
Semper Augustus0.6%$5.74M
Gardner Russo & Quinn<0.1%$211.0K

Latest insider trades

Open-market purchases and sales by Merck & Co., Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 13, 2026 (view filing)5:02 PM ETAug 13Same dayGuindo ChirfiEVP, Access, Policy & CommsSSale−10.0K$135.00−$1.35M−21.5%36.6K after
Aug 13, 2026 (view filing)4:11 PM ETAug 121 dayZachary JenniferEVP, General CounselSSale−80.3K$133.46−$10.7M−63.8%45.5K after
Aug 12, 2026 (view filing)4:10 PM ETAug 10-122 daysDeLuca Richard R.EVP&Pres, Merck Animal HeallthSSale−45.3K$131.12−$5.94M−29.1%110.2K after5 lots
Aug 10, 2026 (view filing)4:28 PM ETAug 64 daysDeLuca Richard R.EVP&Pres, Merck Animal HeallthSSale−6.05K$130.38−$788.8K−3.7%155.5K after3 lots
Aug 7, 2026 (view filing)4:21 PM ETAug 52 daysMaraldo David R.EVP & Pres. MMDSSale−18.7K$128.72−$2.41M−50.7%18.2K after3 lots
Aug 7, 2026 (view filing)4:19 PM ETAug 52 daysWilliams David MichaelEVP,Chief Info&Digital OfficerSSale−52.8K$128.77−$6.81M−62.5%31.7K after3 lots
Aug 7, 2026 (view filing)4:17 PM ETAug 61 dayGuindo ChirfiEVP, Access, Policy & CommsSSale−15.0K$131.00−$1.97M−24.3%46.6K after
Feb 12, 2026 (view filing)Feb 12Same dayGuindo ChirfiChief Marketing OfficerSSale−10.0K$121.46−$1.21M−14.2%60.6K after
Feb 10, 2026 (view filing)Feb 10Same dayLi Dean YExecutive VP & President, MRLSSale−10.2K$117.52−$1.20M−10.0%92.0K after
Feb 9, 2026 (view filing)Feb 9Same dayGuindo ChirfiChief Marketing OfficerSSale−10.0K$118.41−$1.18M−12.4%70.6K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Merck & Co., Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 3,854 holders
Institutions holding MRK in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.226,999,837$29.2B0.43%+1,169,507+0.5%Added
Vanguard Capital Management LLC161,323,174$20.7B0.44%+335,550+0.2%Added
State Street Corp120,413,256$15.6B0.46%+1,087,583+0.9%Added
Wellington Management Group LLP86,249,283$11.1B1.91%+1,934,312+2.3%Added
Vanguard Portfolio Management LLC67,738,969$8.70B0.39%+434,664+0.6%Added
Geode Capital Management, LLC60,744,214$7.79B0.42%+1,186,060+2.0%Added
Charles Schwab Investment Management Inc54,365,289$6.99B0.93%+4,600,064+9.2%Added
Morgan Stanley48,641,158$6.25B0.33%+1,008,671+2.1%Added
FMR LLC45,440,355$5.84B0.25%+924,345+2.1%Added
JPMorgan Chase & Co43,886,420$5.68B0.33%−9,086,563−17.2%Reduced